Fast-track drug discovery timelines by making higher confidence decisions with AI-generated insights and predictions. Deepen your understanding that can lead to groundbreaking discoveries.
ABOUT US
Buliding a comprehensive understanding
BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development.
In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack treatment, our technology can increase the probability of success and reduce timelines.
Our proprietary Benevolent PlatformTM is one of the industry's most established and validated AI drug discovery technologies.
Progress
End-to-end drug discovery offerings
We are continuing to expand our industry-leading collaborations, further validating our drug discovery offerings solutions
Multi-year collaboration with AstraZeneca continues to progress
AstraZeneca is progressing 4 of the most promising targets selected into the AstraZeneca portfolio
Expanding AI-generated pipeline
We are progressing 5 of our most advanced high-potential clinical and preclinical assets. Lead asset, BEN-8744, for the treatment of ulcerative colitis is in a Phase I clinical study
New strategic collaboration with Merck
Multi-year collaboration to identify and develop 3 novel small molecule drug candiates in in oncology, neurology and immunology
Partner with us
We work with leading pharma companies
We partner with pharma to discover novel treatments using our Benevolent Platform™. Our expertise spans across the entire drug discovery process, working across any therapeutic area or drug modality.
Careers
A diverse team passionate about building a healthier future
BenevolentAI embodies a new type of culture based on true collaboration between scientists and technologists. If you are curious and collaborative, we would love to hear from you.
